Tivic Health Systems

Tivic Health Systems FCF/Debt

The Free Cash Flow to Debt Ratio of Tivic Health Systems (TIVC) as of Nov 1, 2026 is -117.45 %. In the previous year, Free Cash Flow to Debt Ratio was -2,338.48 % — a change of -94.98% (higher).

FCF/Debt

-117.45 %

YoY

-94.98%

Last updated:

Free Cash Flow to Debt Ratio of Tivic Health Systems is 2025 -117.45 % . Free Cash Flow to Debt Ratio of Tivic Health Systems was 2024 -2,338.48 % . It decreases by -94.98% higher compared to the previous year.

The Tivic Health Systems FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-370,100.00 USD
Jan 1, 2020
-206.06 USD
Jan 1, 2021
-792.66 USD
Jan 1, 2022
-1,684.91 USD
Jan 1, 2023
-2,338.48 USD
Jan 1, 2025
-117.45 USD
The Tivic Health Systems FCF/Debt history
YEARFCF/DebtYoY
-117.45 %-94.98%
-2,338.48 %+38.79%
-1,684.91 %+112.56%
-792.66 %+284.67%
-206.06 %-99.94%
-370,100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tivic Health Systems Stock analysis

What does Tivic Health Systems do? Tivic Health Systems Inc is a commercial-stage health tech company advancing bioelectronic medicine with patented technology that stimulates trigeminal, sympathetic, and vagus nerve structures. Its first commercial product, ClearUP, is an FDA-approved handheld bioelectronic sinus device clinically proven and doctor-recommended for treating inflammatory chronic conditions. ClearUP is sold directly to consumers in the U.S. through online retailers and commercial distributors, with reseller channels expanding its market reach. The company focuses on expanding its intellectual property portfolio and research programs related to vagus nerve stimulation for broader therapeutic applications. ClearUP serves consumers seeking drug-free therapeutic solutions for sinus conditions, targeting individuals with inflammatory chronic health issues who prefer non-invasive treatments. Healthcare providers recommend ClearUP as a safe, low-risk alternative to medication, appealing to patients looking for high safety profiles in treatment options. The company's revenue streams derive from direct consumer sales and reseller partnerships, leveraging its FDA approval and clinical validation to drive market adoption. Tivic Health Systems develops its products around non-invasive nerve stimulation technology, with ClearUP being the primary revenue-generating product. The company's strategy centers on expanding its IP portfolio to support future product development in bioelectronic medicine, particularly in vagus nerve stimulation applications. By focusing on clinical validation and doctor recommendations, Tivic Health aims to position itself as a leader in drug-free therapeutic solutions for chronic inflammatory conditions. Tivic Health Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tivic Health Systems stock

Free Cash Flow to Debt Ratio of Tivic Health Systems is -117.45 % in 2025.

Free Cash Flow to Debt Ratio of Tivic Health Systems changed from -2,338.48 % to -117.45 %, representing a -94.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Tivic Health Systems since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Tivic Health Systems with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Tivic Health Systems

All Key Metrics — Tivic Health Systems